Oatp1a4 and an L-thyroxine-sensitive transporter mediate the mouse blood-brain barrier transport of amyloid-β peptide

• Published in: Journal of Alzheimer's disease Vol. 36; no. 3; p. 555
• Main Authors: Do, Tuan Minh, Bedussi, Beatrice, Chasseigneaux, Stéphanie, Dodacki, Agnès, Yapo, Cédric, Chacun, Hélène, Scherrmann, Jean-Michel, Farinotti, Robert, Bourasset, Fanchon
• Format: Journal Article
• Language: English
• Published: Netherlands 01-01-2013
• Subjects: Amyloid beta-Peptides - metabolism; Animals; Blood-Brain Barrier - drug effects; Blood-Brain Barrier - metabolism; Fluorobenzenes - pharmacology; Mice; Organic Cation Transport Proteins - metabolism; Protein Transport - drug effects; Protein Transport - physiology; Pyrimidines - pharmacology; Rosuvastatin Calcium; Sulfonamides - pharmacology; Taurocholic Acid - pharmacology; Thyroxine - pharmacology
• ISSN: 1875-8908
• DOI: 10.3233/JAD-121891

The influx of amyloid-β peptide (Aβ) across the blood-brain barrier is partly mediated by the receptor for advanced glycation end products (RAGE). But other transporters, like Oatp (organic anion transporter polypeptide, SLC21) transporters, could also be involved. We used in situ brain perfusion to show that rosuvastatin and taurocholate, two established Oatp1a4 substrates, decreased (5-fold) the Clup of [3H]Aβ while L-thyroxine increased it (5.5-fold). We demonstrated an interaction between Aβ and Oatp1a4 by co-immunoprecipitation and western blotting experiments, supporting the hypothesis that the rosuvastatin- and taurocholate-sensitive transporter was Oatp1a4. In conclusion, our results suggest that, in mice, the brain uptake of Aβ is partly mediated by Oatp1a4 and that L-thyroxine may play a crucial role in the inhibition of brain Aβ clearance.